REFERÊNCIAS BIBLIOGRÁFICAS
Abraham E, Reinhart K, Opal S, et al: Efficacy and safety of tifacogin (recombinant tissue factor
pathway inhibitor) in severe sepsis: a randomized controlled trial.
JAMA 2003; 290(2): 238-47.
Abraham E, Laterre PF, Garg R, et al:
Drotrecogin alfa (activated) for adults with severe sepsis
and a low risk of death.
N Engl J Med 2005; 353(13): 1332-41.
Alberti C, Brun-Buisson C, Goodman SV, et al:
Influence of systemic inflammatory response
syndrome and sepsis on outcome of critically ill infected patients.
Am J Respir Crit Care Med
2003; 168(1): 77-84.
Alberti C, Brun-Buisson C, Chevret S, et al:
Systemic inflammatory response and progression to
severe sepsis in critically ill infected patients.
Am J Respir Crit Care Med 2005; 171(5): 461-8.
Alves-Filho JC, Freitas A, Russo M, et al: Toll-like receptor 4 signaling leads to neutrophil
migration impairment in polimicrobial sepsis. Crit Care Med 2006; 34: 461-470.
Angus CD, Linde-Zwirble WT, Lidicker J, et al: Epidemiology of severe sepsis in the United
States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;
29: 1303-1309.
Arts DG, Keizer NF, Vroom MB, et al:
Reliability and accuracy of Sequential Organ Failure
Assessment (SOFA) scoring.
Crit Care Med 2005; 33(9): 1988-93.
Barie PS, Hydo LJ, Shou J, Eachempati SR. Efficacy and safety of drotrecogin alfa (activated)
for the therapy of surgical patients with severe sepsis.
Surg Infect (Larchmt) 2006; 7 Suppl 2:
S77-80.
Bernard GR, Ely EW, Wright TJ, et al: Safety and dose relationship of recombinant human
activated protein C for coagulopathy in severe sepsis. Crit Care Med 2001; 29:2051–2059
Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated
protein C for severe sepsis. N Engl J Med 2001; 344:699–709 (PROWESS).
Chittock DR; Dhingra VK; Ronco JJ, et al: Severity of illness and risk of death associated with
pulmonary artery catheter use.
Crit Care Med 2004; 32(4): 911-5.
Dellinger RP, Carlet JM, Masur H, et al.
Surviving Sepsis Campaign guidelines for management
of severe sepsis and septic shock.
Crit Care Med 2004; 32(3): 858-73.
Dhainaut JF, Laterre PF, LaRosa SP, et al: The clinical evaluation committee in a large
multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis
(PROWESS): Role, methodology, and results. Crit Care Med 2003 ; 31 : 2291–2301.
Dhainaut JF, Yan SB, Caessens YE, et al:
Protein C/activated protein C pathway: overview of
clinical trial results in severe sepsis.
Crit Care Med 2004; 32(5 Suppl): S194-201.
Eichacker PQ, Danner RL, Suffredine AF, et al:
Reassessing recombinant human activated
protein C for sepsis: time for a new randomized controlled trial.
Crit Care Med 2005; 33(10):
2426-8.
Eichacker PQ, Natanson C, Danner RL:
Surviving sepsis--practice guidelines, marketing
campaigns, and Eli Lilly.
N Engl J Med 2006; 355(16): 1640-2.
Eisele B, Lamy M, Thijis LG, et al: Antithrombin III in patients with severe sepsis. A randomized,
placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized,
placebo-controlled, double-blind trials with antithrombin III in severe sepsis.
Intensive Care Med
1998; 24(7): 663-72.
31